Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) FCF Margin (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed FCF Margin for 3 consecutive years, with 381.64% as the latest value for Q1 2025.

  • Quarterly FCF Margin changed N/A to 381.64% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 1293.75% through Dec 2025, changed N/A year-over-year, with the annual reading at 1294.59% for FY2025, N/A changed from the prior year.
  • FCF Margin for Q1 2025 was 381.64% at Centessa Pharmaceuticals, down from 1209.26% in the prior quarter.
  • The five-year high for FCF Margin was 3636.18% in Q2 2022, with the low at 381.64% in Q1 2025.
  • Average FCF Margin over 3 years is 1948.32%, with a median of 2034.55% recorded in 2022.
  • Peak annual rise in FCF Margin hit -56131bps in 2023, while the deepest fall reached -183732bps in 2023.
  • Over 3 years, FCF Margin stood at 2370.22% in 2022, then tumbled by -49bps to 1209.26% in 2023, then plummeted by -132bps to 381.64% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 381.64%, 1209.26%, and 1473.24% for Q1 2025, Q4 2023, and Q3 2023 respectively.